A Phase I, Single-Centre, Randomised, Double-Blind, Placebo-Controlled Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2516 in Young and Elderly Healthy Volunteers After Oral Single Ascending Doses
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2008
At a glance
- Drugs AZD 2516 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- 12 Dec 2008 Status changed from recruiting to completed, according to ClinicalTrials.gov.
- 13 Nov 2008 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov.
- 17 Sep 2008 New trial record.